Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies.

Trial Profile

A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies.

Phase of Trial: Phase I/II

Latest Information Update: 10 Dec 2013

At a glance

  • Drugs Pacritinib (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors S*BIO
  • Most Recent Events

    • 10 Dec 2013 Pooled analysis assessing outcomes in patients with no more than 100,000 platelets/microL at baseline presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 28 Jun 2013 Pooled safety results of this trial and 3 other phase I and II trials will be presented at the 18th Congress of the European Hematology Association in June 2013. Results also published in a Cell Therapeutics media release.
    • 19 Apr 2012 Actual end date Jan 2012 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top